Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of BI 1265162
NCT04267276Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 1265162 in cystic fibrosis (CF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Mass Balance Recovery of Total (C-14) BI 1265162-radioactivity in Urine and Mass Balance Recovery of Total (C-14) BI 1265162-radioactivity in Faeces. Started Feb 2020; status: terminated.
02
Drugs
BI 1265162
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04267276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267276.